Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) announced that it has expanded its clinical research capabilities into Arizona with a new site in Phoenix, where the company operates mental health clinics.
The site is Numinus' third clinical trial research site in the US, and fifth research site overall. It will offer clinical research management services, focused on advancing psychedelic science through Cedar Clinical Research (CCR).
"By expanding into Phoenix, we can scale our clinical research capabilities, allowing us to offer our current clients faster services and an expanded network of participants, while welcoming a growing list of biotech and psychedelic organizations," noted Paul Thielking, chief research officer at Numinus in a statement.
"The site is fully staffed – drawing on our clinic-base of renowned researchers and practitioners, so we can start operations as soon as possible," he added.
READ: Numinus receives clinical trial application approval from Health Canada for experiential psychedelic-assisted therapy training using Psilocybe cubensis tea
The new site is located within an existing leased facility, next to one of Numinus' established wellness clinics, to fully utilize available clinical space. The first clinical trial operating out of the new site will begin in early March with a site inspection visit before beginning the recruitment phase later that month, the company said.
"The addition of this new clinical research site further cements Numinus as one of the leading research platforms for the sector's companies and institutions who sponsor clinical trials in the mental health and psychedelic space, allowing them to leverage our extensive resources and management offering," said Numinus CEO and co-founder Payton Nyquvest.
"Ultimately, this allows Numinus to support the growing body of research in the mental health and psychedelic space as we all work towards the goal of more indication-based evidence and safety data," he added.
In Numinus' most recent reported quarter (for the three months ended November 30, 2022), CCR managed 14 clinical trials for third-party biotech and psychedelics sector companies, which included 191 clinical trial participants.
In addition to its five clinical research sites, Numinus also operates a Health Canada-licensed lab which develops proprietary intellectual property and focuses on advancing psychedelic discoveries.
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental healthcare and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use.
Contact the author at jon.hopkins@proactiveinvestors.com